Level B· Emerging clinical evidence with positive signalsClinical TrialPubMedOpen access

Mesenchymal stem cell-derived exosomes in myocardial infarction repair: therapeutic potential and scaffold-based delivery strategies.

Azimian Zavareh V., Eslampoor N., Panahi-Alanagh S., Malekmohammad L., Stanek A.

Clinical Trial on Cardiovascular Disease, published in Front Pharmacol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Front Pharmacol (2026)
Country
Switzerland
Reported sample size
—
Source database
PubMed
PMID
41727547
PMCID
PMC12916389
DOI
10.3389/fphar.2026.1762630
Citations
1

Abstract (original English)

Myocardial infarction (MI) remains a leading cause of global mortality, with current therapeutic modalities offering limited capacity for complete myocardial tissue regeneration. Advances in regenerative medicine have introduced stem cell-based approaches, among which mesenchymal stem cells (MSCs) have garnered significant scientific curiosity due to their multipotent differentiation potential and favorable safety profile. However, evidence suggests that the primary therapeutic effects of MSCs are mediated through their paracrine secretion of bioactive factors, notably exosomes. These MSC-derived exosomes (MSC-Exos) can modulate key aspects of cardiac repair, such as enhancing angiogenesis, preventing apoptosis, and alleviating inflammation by transferring genetic material such as miRNAs, proteins, and lipids and by activating molecular pathways critical to cardiac repair. Numerous studies as well as preclinical and clinical trials are currently investigating MSC-Exos for tissue regeneration. This review critically examines the biological characteristics and underlying mechanisms of MSC-Exos in myocardial repair, with particular focus on cell sources such as bone marrow-derived MSCs (BMMSCs), adipose-derived MSCs (ADSCs), and human umbilical cord MSCs (HUCMSCs), and evaluates their roles from multiple perspectives. Moreover, this review emphasizes innovative delivery approaches

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research